



Clinical trial results:

A Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Emetogenic Chemotherapy in Adolescent Patients

Summary

EudraCT number	2014-004603-78
Trial protocol	Outside EU/EEA
Global end of trial date	19 February 2007

Results information

Result version number	v2 (current)
This version publication date	12 May 2016
First version publication date	01 August 2015
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	0869-097
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00080444
WHO universal trial number (UTN)	-
Other trial identifiers	Merck protocol number: MK-0869-097

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000144-PIP01-07
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	19 February 2007
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	19 February 2007
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to estimate the difference for the percentage of adolescent participants treated with aprepitant triple therapy or standard therapy who have one or more clinical or laboratory drug-related adverse experience(s) during the Cycle 1 study-drug therapy period plus 14 days post-therapy. The duration of treatment was the first 4 days of one 28-day cycle (Cycle 1). In the double-blind Part 1 of this study, enrolled participants were to be randomized to receive either aprepitant triple therapy or standard therapy. Participants who successfully completed Cycle 1 may have been eligible to participate for 9 subsequent optional, open-label, 28-day cycles. In Part 2 of this study, all enrolled participants were to receive open-label aprepitant.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research. The following additional measure defined for this individual study was in place for the protection of trial subjects: Participants may have been provided with a prescription for rescue therapy to relieve symptoms of nausea or vomiting according to investigator selection. Permitted rescue therapies were: 5-hydroxytryptamine (5-HT₃) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines or benzamides (e.g., metoclopramide or alizapride). In addition, participants receiving multi-day chemotherapy regimens were permitted to receive preventative antiemetic treatment with a 5-HT₃ antagonist if clinically indicated.

Background therapy:

All participants received intravenous (IV) ondansetron on treatment Days 1 and 2 and oral (PO) dexamethasone on Day 1 and Days 2 to 4.

Evidence for comparator: -

Actual start date of recruitment	05 April 2004
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 1
Country: Number of subjects enrolled	United States: 28
Country: Number of subjects enrolled	Brazil: 21
Worldwide total number of subjects	50
EEA total number of subjects	0

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	1
Adolescents (12-17 years)	47
Adults (18-64 years)	2
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Participants aged 12 to 17 years who had confirmed malignancies and were to be treated with an emetogenic chemotherapy regimen were enrolled into this study.

Period 1

Period 1 title	Cycle 1
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Aprepitant Triple Therapy: Cycle 1

Arm description:

Cycle 1: Participants received one aprepitant 125 mg capsule PO on Day 1 and one aprepitant 80 mg capsule PO on Days 2 and 3 plus ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2 plus one dexamethasone 8 mg tablet PO on Day 1 and one dexamethasone 4 mg tablet PO on Days 2 to 4. After completion of Cycle 1, participants had the option to continue in the study for up to 9 additional cycles, for a total of 10 cycles of treatment. Cycles 2-10: Participants received open-label aprepitant triple therapy.

Arm type	Experimental
Investigational medicinal product name	Aprepitant
Investigational medicinal product code	
Other name	EMEND®, MK-0869
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Aprepitant 125 mg capsule PO on Day 1 and aprepitant 80 mg capsule PO on Days 2 and 3

Investigational medicinal product name	Dexamethasone
Investigational medicinal product code	
Other name	DECADRON®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Dexamethasone 8 mg tablet PO on Day 1 and dexamethasone 4 mg tablet PO on Days 2 to 4 for the Aprepitant Triple Therapy group OR Dexamethasone 16 mg tablet PO on Day 1 and dexamethasone 8 mg tablet PO on Days 2 to 4 for the Standard Therapy group

Investigational medicinal product name	Ondansetron
Investigational medicinal product code	
Other name	ZOFTRAN®
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2

Arm title	Standard Therapy: Cycle 1
------------------	---------------------------

Arm description:

Cycle 1: Participants received placebo to aprepitant 125 mg PO on Day 1 and placebo to aprepitant 80

mg PO on Days 2 and 3 plus ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2 plus one dexamethasone 16 mg tablet PO on Day 1 and one dexamethasone 8 mg tablet PO on Days 2 to 4. After completion of Cycle 1, participants had the option to continue in the study for up to 9 additional cycles, for a total of 10 cycles of treatment. Cycles 2-10: Participants received open-label aprepitant triple therapy.

Arm type	Active comparator
Investigational medicinal product name	Ondansetron
Investigational medicinal product code	
Other name	ZOFRAN®
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravascular use

Dosage and administration details:

Ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2

Investigational medicinal product name	Placebo to aprepitant
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Placebo to aprepitant 125 mg PO on Day 1 and Placebo to aprepitant 80 mg PO on Days 2 and 3

Investigational medicinal product name	Dexamethasone
Investigational medicinal product code	
Other name	DECADRON®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Dexamethasone 8 mg tablet PO on Day 1 and dexamethasone 4 mg tablet PO on Days 2 to 4 for the Aprepitant Triple Therapy group OR Dexamethasone 16 mg tablet PO on Day 1 and dexamethasone 8 mg tablet PO on Days 2 to 4 for the Standard Therapy group

Number of subjects in period 1	Aprepitant Triple Therapy: Cycle 1	Standard Therapy: Cycle 1
Started	32	18
Completed	31	18
Not completed	1	0
Not specified	1	-

Period 2

Period 2 title	Cycles 2-10
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

All study drug was open label; no blinding was needed. All participants received open-label aprepitant.

Arms

Are arms mutually exclusive?	No
------------------------------	----

Arm title	Aprepitant Triple Therapy: Cycles 2-10
Arm description:	
Cycle 1: Participants received one aprepitant 125 mg capsule PO on Day 1 and one aprepitant 80 mg capsule PO on Days 2 and 3 plus ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2 plus one dexamethasone 8 mg tablet PO on Day 1 and one dexamethasone 4 mg tablet PO on Days 2 to 4. After completion of Cycle 1, participants had the option to continue in the study for up to 9 additional cycles, for a total of 10 cycles of treatment. Cycles 2-10: Participants received open-label aprepitant triple therapy.	
Arm type	Experimental
Investigational medicinal product name	Aprepitant
Investigational medicinal product code	
Other name	EMEND®, MK-0869
Pharmaceutical forms	Capsule
Routes of administration	Oral use
Dosage and administration details:	
Aprepitant 125 mg capsule PO on Day 1 and aprepitant 80 mg capsule PO on Days 2 and 3	
Investigational medicinal product name	Ondansetron
Investigational medicinal product code	
Other name	ZOFRAN®
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2	
Investigational medicinal product name	Dexamethasone
Investigational medicinal product code	
Other name	DECADRON®
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Dexamethasone 8 mg tablet PO on Day 1 and dexamethasone 4 mg tablet PO on Days 2 to 4 for the Aprepitant Triple Therapy group OR Dexamethasone 16 mg tablet PO on Day 1 and dexamethasone 8 mg tablet PO on Days 2 to 4 for the Standard Therapy group	
Arm title	Standard Therapy: Cycles 2-10
Arm description:	
Cycle 1: Participants received placebo to aprepitant 125 mg PO on Day 1 and placebo to aprepitant 80 mg PO on Days 2 and 3 plus ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2 plus one dexamethasone 16 mg tablet PO on Day 1 and one dexamethasone 8 mg tablet PO on Days 2 to 4. After completion of Cycle 1, participants had the option to continue in the study for up to 9 additional cycles, for a total of 10 cycles of treatment. Cycles 2-10: Participants received open-label aprepitant triple therapy.	
Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 2	Aprepitant Triple Therapy: Cycles 2-10	Standard Therapy: Cycles 2-10
Started	29	16
Completed	36	0
Not completed	9	16
Consent withdrawn by subject	2	-
Not specified	5	-

Transferred to other arm/group	-	16
Protocol deviation	2	-
Joined	16	0
Transferred in from other group/arm	16	-

Baseline characteristics

Reporting groups

Reporting group title	Aprepitant Triple Therapy: Cycle 1
-----------------------	------------------------------------

Reporting group description:

Cycle 1: Participants received one aprepitant 125 mg capsule PO on Day 1 and one aprepitant 80 mg capsule PO on Days 2 and 3 plus ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2 plus one dexamethasone 8 mg tablet PO on Day 1 and one dexamethasone 4 mg tablet PO on Days 2 to 4. After completion of Cycle 1, participants had the option to continue in the study for up to 9 additional cycles, for a total of 10 cycles of treatment. Cycles 2-10: Participants received open-label aprepitant triple therapy.

Reporting group title	Standard Therapy: Cycle 1
-----------------------	---------------------------

Reporting group description:

Cycle 1: Participants received placebo to aprepitant 125 mg PO on Day 1 and placebo to aprepitant 80 mg PO on Days 2 and 3 plus ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2 plus one dexamethasone 16 mg tablet PO on Day 1 and one dexamethasone 8 mg tablet PO on Days 2 to 4. After completion of Cycle 1, participants had the option to continue in the study for up to 9 additional cycles, for a total of 10 cycles of treatment. Cycles 2-10: Participants received open-label aprepitant triple therapy.

Reporting group values	Aprepitant Triple Therapy: Cycle 1	Standard Therapy: Cycle 1	Total
Number of subjects	32	18	50
Age categorical Units: Subjects			
Children (2-11 years)	0	1	1
Adolescents (12-17 years)	30	17	47
Adults (18-64 years)	2	0	2
Age continuous Units: years			
arithmetic mean	15	14.6	
standard deviation	± 1.7	± 1.9	-
Gender categorical Units: Subjects			
Female	8	6	14
Male	24	12	36

End points

End points reporting groups

Reporting group title	Aprepitant Triple Therapy: Cycle 1
Reporting group description: Cycle 1: Participants received one aprepitant 125 mg capsule PO on Day 1 and one aprepitant 80 mg capsule PO on Days 2 and 3 plus ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2 plus one dexamethasone 8 mg tablet PO on Day 1 and one dexamethasone 4 mg tablet PO on Days 2 to 4. After completion of Cycle 1, participants had the option to continue in the study for up to 9 additional cycles, for a total of 10 cycles of treatment. Cycles 2-10: Participants received open-label aprepitant triple therapy.	
Reporting group title	Standard Therapy: Cycle 1
Reporting group description: Cycle 1: Participants received placebo to aprepitant 125 mg PO on Day 1 and placebo to aprepitant 80 mg PO on Days 2 and 3 plus ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2 plus one dexamethasone 16 mg tablet PO on Day 1 and one dexamethasone 8 mg tablet PO on Days 2 to 4. After completion of Cycle 1, participants had the option to continue in the study for up to 9 additional cycles, for a total of 10 cycles of treatment. Cycles 2-10: Participants received open-label aprepitant triple therapy.	
Reporting group title	Aprepitant Triple Therapy: Cycles 2-10
Reporting group description: Cycle 1: Participants received one aprepitant 125 mg capsule PO on Day 1 and one aprepitant 80 mg capsule PO on Days 2 and 3 plus ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2 plus one dexamethasone 8 mg tablet PO on Day 1 and one dexamethasone 4 mg tablet PO on Days 2 to 4. After completion of Cycle 1, participants had the option to continue in the study for up to 9 additional cycles, for a total of 10 cycles of treatment. Cycles 2-10: Participants received open-label aprepitant triple therapy.	
Reporting group title	Standard Therapy: Cycles 2-10
Reporting group description: Cycle 1: Participants received placebo to aprepitant 125 mg PO on Day 1 and placebo to aprepitant 80 mg PO on Days 2 and 3 plus ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2 plus one dexamethasone 16 mg tablet PO on Day 1 and one dexamethasone 8 mg tablet PO on Days 2 to 4. After completion of Cycle 1, participants had the option to continue in the study for up to 9 additional cycles, for a total of 10 cycles of treatment. Cycles 2-10: Participants received open-label aprepitant triple therapy.	

Primary: Percentage of Participants Who Experience At Least One Drug-related Adverse Event (AE) in Cycle 1

End point title	Percentage of Participants Who Experience At Least One Drug-related Adverse Event (AE) in Cycle 1 ^[1]
End point description: An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of study drug, is also an AE. Drug-related AEs were those AEs judged by the investigator to be definitely, probably or possibly related to study drug. Drug-related clinical and laboratory AEs are combined.	
End point type	Primary
End point timeframe: Up to 14 days after last dose of study drug in Cycle 1 (Up to 17 days)	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No statistical analyses were planned for this end point.	

End point values	Aprepitant Triple Therapy: Cycle 1	Standard Therapy: Cycle 1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32 ^[2]	18 ^[3]		
Units: Percentage of participants				
number (not applicable)	21.9	5.6		

Notes:

[2] - All randomized participants who received ≥ 1 dose of study drug.

[3] - All randomized participants who received ≥ 1 dose of study drug.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Who Experience At Least One Serious AE in Cycle 1

End point title	Percentage of Participants Who Experience At Least One Serious AE in Cycle 1
-----------------	--

End point description:

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of study drug, is also an AE. A serious AE (SAE) is any adverse experience occurring at any dose that: Results in death, Is life threatening, Results in a persistent or significant disability/incapacity, Results in or prolongs an existing inpatient hospitalization, Is a congenital anomaly/birth defect, Is a cancer. Clinical and laboratory SAEs are combined.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 14 days after last dose of study drug in Cycle 1 (Up to 17 days)

End point values	Aprepitant Triple Therapy: Cycle 1	Standard Therapy: Cycle 1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32 ^[4]	18 ^[5]		
Units: Percentage of participants				
number (not applicable)	31.3	11.1		

Notes:

[4] - All randomized participants who received ≥ 1 dose of study drug.

[5] - All randomized participants who received ≥ 1 dose of study drug.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Who Experience At Least One Serious Drug-related AE

End point title	Percentage of Participants Who Experience At Least One Serious Drug-related AE
-----------------	--

End point description:

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the

use of study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of study drug, is also an AE. A serious AE (SAE) is any adverse experience occurring at any dose that: Results in death, Is life threatening, Results in a persistent or significant disability/incapacity, Results in or prolongs an existing inpatient hospitalization, Is a congenital anomaly/birth defect, Is a cancer. Drug-related AEs were those AEs judged by the investigator to be definitely, probably or possibly related to study drug. Drug-related clinical and laboratory SAEs are combined.

End point type	Secondary
End point timeframe:	
Up to 14 days after last dose of study drug (Up to 10.5 months)	

End point values	Aprepitant Triple Therapy: Cycle 1	Aprepitant Triple Therapy: Cycles 2-10	Standard Therapy: Cycle 1	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32 ^[6]	45 ^[7]	18 ^[8]	
Units: Percentage of participants				
number (not applicable)	0	0	0	

Notes:

[6] - All randomized participants who received ≥ 1 dose of study drug.

[7] - All randomized participants who received ≥ 1 dose of study drug.

[8] - All randomized participants who received ≥ 1 dose of study drug.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Who Discontinue Study Drug Due to an AE

End point title	Percentage of Participants Who Discontinue Study Drug Due to an AE
-----------------	--

End point description:

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of study drug. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of study drug, is also an AE.

End point type	Secondary
End point timeframe:	
Up to 10 cycles (Up to 10 months)	

End point values	Aprepitant Triple Therapy: Cycle 1	Aprepitant Triple Therapy: Cycles 2-10	Standard Therapy: Cycle 1	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	32 ^[9]	45 ^[10]	18 ^[11]	
Units: Percentage of participants				
number (not applicable)	0	0	0	

Notes:

[9] - All randomized participants who received ≥ 1 dose of study drug.

[10] - All randomized participants who received ≥ 1 dose of study drug.

[11] - All randomized participants who received ≥ 1 dose of study drug.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants With a Complete Response in Cycle 1

End point title	Percentage of Participants With a Complete Response in Cycle 1
-----------------	--

End point description:

A complete response was defined as no vomiting and no use of rescue medication. Overall Phase = 0 to 120 hours following initiation of chemotherapy. Acute Phase = 0 to 24 hours following initiation of chemotherapy. Delayed Phase = 25 to 120 hours following initiation of chemotherapy.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 120 hours following initiation of chemotherapy in Cycle 1

End point values	Aprepitant Triple Therapy: Cycle 1	Standard Therapy: Cycle 1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28 ^[12]	18 ^[13]		
Units: Percentage of participants				
number (not applicable)				
Overall Phase	28.6	5.6		
Acute Phase	60.7	38.9		
Delayed Phase	35.7	5.6		

Notes:

[12] - Participants received chemotherapy & ≥ 1 study drug regimen & had ≥ 1 post-treatment efficacy value.

[13] - Participants received chemotherapy & ≥ 1 study drug regimen & had ≥ 1 post-treatment efficacy value.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Who Experienced No Vomiting in Cycle 1

End point title	Percentage of Participants Who Experienced No Vomiting in Cycle 1
-----------------	---

End point description:

The percentage of participants who experienced no vomiting episodes during Cycle 1 is presented. Overall Phase = 0 to 120 hours following initiation of chemotherapy. Acute Phase = 0 to 24 hours following initiation of chemotherapy. Delayed Phase = 25 to 120 hours following initiation of chemotherapy.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 120 hours after initiation of chemotherapy in Cycle 1

End point values	Aprepitant Triple Therapy: Cycle 1	Standard Therapy: Cycle 1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	28 ^[14]	18 ^[15]		
Units: Percentage of participants				
number (not applicable)				
Overall Phase	32.1	5.6		
Acute Phase	64.3	44.4		
Delayed Phase	39.3	5.6		

Notes:

[14] - Participants received chemotherapy & ≥1 study drug regimen & had ≥1 post-treatment efficacy value.

[15] - Participants received chemotherapy & ≥1 study drug regimen & had ≥1 post-treatment efficacy value.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Who Experienced No Nausea in Cycle 1

End point title	Percentage of Participants Who Experienced No Nausea in Cycle 1
-----------------	---

End point description:

The percentage of participants who experienced no nausea during Cycle 1 is presented. Nausea was defined as having nausea such that it interfered with a participant's usual daily activities. Overall Phase = 0 to 120 hours following initiation of chemotherapy.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 120 hours following initiation of chemotherapy in Cycle 1

End point values	Aprepitant Triple Therapy: Cycle 1	Standard Therapy: Cycle 1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27 ^[16]	17 ^[17]		
Units: Percentage of participants				
number (not applicable)	44.4	17.6		

Notes:

[16] - Participants received chemotherapy & ≥1 study drug regimen & had ≥1 post-treatment efficacy value.

[17] - Participants received chemotherapy & ≥1 study drug regimen & had ≥1 post-treatment efficacy value.

Statistical analyses

No statistical analyses for this end point

Secondary: Aprepitant Area Under the Time-concentration Curve From 0 to 24 Hours (AUC0-24hr)

End point title	Aprepitant Area Under the Time-concentration Curve From 0 to 24 Hours (AUC0-24hr)
End point description: Three (3) mL of blood were to be collected to measure aprepitant pharmacokinetics at predose (-2 hours), 1 (prior to chemotherapy infusion) 2, 3, 4, 8, 12, and 24 hours post aprepitant dose on Day 1. No participants in the Standard Therapy group received aprepitant during Cycle 1.	
End point type	Secondary
End point timeframe: Up to 24 hours following aprepitant administration	

End point values	Aprepitant Triple Therapy: Cycle 1	Standard Therapy: Cycle 1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18 ^[18]	0 ^[19]		
Units: ng*hr/mL				
geometric mean (confidence interval 95%)	14318.4 (11106.7 to 18458.9)	(to)		

Notes:

[18] - Participants who received chemotherapy & aprepitant regimen & had pharmacokinetic data.

[19] - No participants in the Standard Therapy group received aprepitant during Cycle 1.

Statistical analyses

No statistical analyses for this end point

Secondary: Aprepitant Maximum Plasma Concentration (Cmax)

End point title	Aprepitant Maximum Plasma Concentration (Cmax)
End point description: Three (3) mL of blood were to be collected to measure aprepitant pharmacokinetics at predose (-2 hours), 1 (prior to chemotherapy infusion) 2, 3, 4, 8, 12, and 24 hours post aprepitant dose on Day 1 and at 24 hours post aprepitant dose on Days 2 (i.e., Day 3) and 3 (i.e., Day 4). No participants in the Standard Therapy group received aprepitant during Cycle 1.	
End point type	Secondary
End point timeframe: Up to 4 days following aprepitant administration	

End point values	Aprepitant Triple Therapy: Cycle 1	Standard Therapy: Cycle 1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	18 ^[20]	0 ^[21]		
Units: ng/mL				
geometric mean (confidence interval 95%)	1070.1 (828 to 1383)	(to)		

Notes:

[20] - Participants who received chemotherapy & aprepitant regimen & had pharmacokinetic data.

[21] - No participants in the Standard Therapy group received aprepitant during Cycle 1.

Statistical analyses

No statistical analyses for this end point

Secondary: Aprepitant Plasma Concentration at 24 Hours Post-dose (C24hr)

End point title	Aprepitant Plasma Concentration at 24 Hours Post-dose (C24hr)
-----------------	---

End point description:

Three (3) mL of blood were to be collected to measure aprepitant pharmacokinetics at 24 hours post aprepitant dose on Day 1. No participants in the Standard Therapy group received aprepitant during Cycle 1.

End point type	Secondary
----------------	-----------

End point timeframe:

24 hours following aprepitant administration

End point values	Aprepitant Triple Therapy: Cycle 1	Standard Therapy: Cycle 1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9 ^[22]	0 ^[23]		
Units: ng/mL				
geometric mean (confidence interval 95%)	449.7 (327 to 618.6)	(to)		

Notes:

[22] - Participants who received chemotherapy & aprepitant regimen & had pharmacokinetic data.

[23] - No participants in the Standard Therapy group received aprepitant during Cycle 1.

Statistical analyses

No statistical analyses for this end point

Secondary: Aprepitant Plasma Concentration at 48 Hours Post-dose (C48hr)

End point title	Aprepitant Plasma Concentration at 48 Hours Post-dose (C48hr)
-----------------	---

End point description:

Three (3) mL of blood were to be collected to measure aprepitant pharmacokinetics at 24 hours post aprepitant dose on Day 2 (i.e., Day 3). No participants in the Standard Therapy group received aprepitant during Cycle 1.

End point type	Secondary
----------------	-----------

End point timeframe:

48 hours following aprepitant administration

End point values	Aprepitant Triple Therapy: Cycle 1	Standard Therapy: Cycle 1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8 ^[24]	0 ^[25]		
Units: ng/mL				
geometric mean (confidence interval 95%)	460.5 (260.1 to 815.4)	(to)		

Notes:

[24] - Participants who received chemotherapy & aprepitant regimen & had pharmacokinetic data.

[25] - No participants in the Standard Therapy group received aprepitant during Cycle 1.

Statistical analyses

No statistical analyses for this end point

Secondary: Aprepitant Plasma Concentration at 72 Hours Post-dose (C72hr)

End point title	Aprepitant Plasma Concentration at 72 Hours Post-dose (C72hr)
-----------------	---

End point description:

Three (3) mL of blood were to be collected to measure aprepitant pharmacokinetics at 24 hours post aprepitant dose on Day 3 (i.e., Day 4). No participants in the Standard Therapy group received aprepitant during Cycle 1.

End point type	Secondary
----------------	-----------

End point timeframe:

72 hours following aprepitant administration

End point values	Aprepitant Triple Therapy: Cycle 1	Standard Therapy: Cycle 1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	16 ^[26]	0 ^[27]		
Units: ng/mL				
geometric mean (confidence interval 95%)	367 (223.4 to 602.9)	(to)		

Notes:

[26] - Participants who received chemotherapy & aprepitant regimen & had pharmacokinetic data.

[27] - No participants in the Standard Therapy group received aprepitant during Cycle 1.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 10.5 months (Up to 2 weeks after last dose of study drug)

Adverse event reporting additional description:

The safety population consisted of all randomized participants who received at least one dose of study drug.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	9.1
--------------------	-----

Reporting groups

Reporting group title	Aprepitant Triple Therapy: Cycle 1
-----------------------	------------------------------------

Reporting group description:

Cycle 1: Participants received one aprepitant 125 mg capsule PO on Day 1 and one aprepitant 80 mg capsule PO on Days 2 and 3 plus ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2 plus one dexamethasone 8 mg tablet PO on Day 1 and one dexamethasone 4 mg tablet PO on Days 2 to 4. After completion of Cycle 1, participants had the option to continue in the study for up to 9 additional cycles, for a total of 10 cycles of treatment. Cycles 2-10: Participants received open-label aprepitant triple therapy.

Reporting group title	Aprepitant Triple Therapy: Cycles 2-10
-----------------------	--

Reporting group description:

Cycles 2-10: All participants received one aprepitant 125 mg capsule PO on Day 1 and one aprepitant 80 mg capsule PO on Days 2 and 3 plus ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2 plus one dexamethasone 8 mg tablet PO on Day 1 and one dexamethasone 4 mg tablet PO on Days 2 to 4.

Reporting group title	Standard Therapy: Cycle 1
-----------------------	---------------------------

Reporting group description:

Cycle 1: Participants received placebo to aprepitant 125 mg PO on Day 1 and placebo to aprepitant 80 mg PO on Days 2 and 3 plus ondansetron solution (0.15 mg/kg x 3 doses) IV on Days 1 and 2 plus one dexamethasone 16 mg tablet PO on Day 1 and one dexamethasone 8 mg tablet PO on Days 2 to 4. After completion of Cycle 1, participants had the option to continue in the study for up to 9 additional cycles, for a total of 10 cycles of treatment. Cycles 2-10: Participants received open-label aprepitant triple therapy.

Serious adverse events	Aprepitant Triple Therapy: Cycle 1	Aprepitant Triple Therapy: Cycles 2-10	Standard Therapy: Cycle 1
Total subjects affected by serious adverse events			
subjects affected / exposed	10 / 32 (31.25%)	19 / 45 (42.22%)	2 / 18 (11.11%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Investigations			
Blood magnesium increased			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoglobin decreased			

subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Weight decreased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 45 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
White blood cell count decreased			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Overdose			
subjects affected / exposed	1 / 32 (3.13%)	0 / 45 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Convulsion			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	8 / 32 (25.00%)	12 / 45 (26.67%)	2 / 18 (11.11%)
occurrences causally related to treatment / all	0 / 8	0 / 17	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Granulocytopenia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Caecitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 45 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 32 (3.13%)	0 / 45 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Cystitis haemorrhagic			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site infection			

subjects affected / exposed	0 / 32 (0.00%)	0 / 45 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	1 / 32 (3.13%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 32 (0.00%)	2 / 45 (4.44%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 32 (0.00%)	2 / 45 (4.44%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative infection			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 45 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	0 / 32 (0.00%)	1 / 45 (2.22%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Aprepitant Triple Therapy: Cycle 1	Aprepitant Triple Therapy: Cycles 2-10	Standard Therapy: Cycle 1
Total subjects affected by non-serious adverse events			
subjects affected / exposed	23 / 32 (71.88%)	1 / 45 (2.22%)	14 / 18 (77.78%)
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	2 / 32 (6.25%)	0 / 45 (0.00%)	1 / 18 (5.56%)
occurrences (all)	2	0	1
Blood potassium decreased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 45 (0.00%)	2 / 18 (11.11%)
occurrences (all)	1	0	2
Blood sodium decreased			
subjects affected / exposed	0 / 32 (0.00%)	0 / 45 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Haemoglobin decreased			
subjects affected / exposed	1 / 32 (3.13%)	0 / 45 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1

Neutrophil count decreased subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3	0 / 45 (0.00%) 0	4 / 18 (22.22%) 5
Platelet count decreased subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 45 (0.00%) 0	1 / 18 (5.56%) 1
Red blood cell count decreased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 45 (0.00%) 0	1 / 18 (5.56%) 1
Weight decreased subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 45 (0.00%) 0	0 / 18 (0.00%) 0
White blood cell count decreased subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3	0 / 45 (0.00%) 0	3 / 18 (16.67%) 3
White blood cells urine positive subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 45 (0.00%) 0	1 / 18 (5.56%) 1
Vascular disorders			
Flushing subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 45 (0.00%) 0	0 / 18 (0.00%) 0
Hypotension subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 45 (0.00%) 0	0 / 18 (0.00%) 0
Pallor subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 45 (0.00%) 0	1 / 18 (5.56%) 1
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	5 / 32 (15.63%) 6	0 / 45 (0.00%) 0	0 / 18 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	6 / 32 (18.75%) 7	0 / 45 (0.00%) 0	1 / 18 (5.56%) 2
Blood and lymphatic system disorders			

Neutropenia subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3	1 / 45 (2.22%) 1	0 / 18 (0.00%) 0
Granulocytopenia subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 45 (0.00%) 0	1 / 18 (5.56%) 1
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 45 (0.00%) 0	1 / 18 (5.56%) 1
Fatigue subjects affected / exposed occurrences (all)	5 / 32 (15.63%) 5	1 / 45 (2.22%) 1	0 / 18 (0.00%) 0
Mucosal inflammation subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 4	0 / 45 (0.00%) 0	0 / 18 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 45 (0.00%) 0	1 / 18 (5.56%) 1
Pyrexia subjects affected / exposed occurrences (all)	4 / 32 (12.50%) 4	0 / 45 (0.00%) 0	1 / 18 (5.56%) 1
Eye disorders			
Conjunctival hyperaemia subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 45 (0.00%) 0	1 / 18 (5.56%) 1
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 45 (0.00%) 0	1 / 18 (5.56%) 1
Abdominal pain upper subjects affected / exposed occurrences (all)	5 / 32 (15.63%) 6	0 / 45 (0.00%) 0	0 / 18 (0.00%) 0
Constipation subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 45 (0.00%) 0	0 / 18 (0.00%) 0

Diarrhoea			
subjects affected / exposed	3 / 32 (9.38%)	0 / 45 (0.00%)	1 / 18 (5.56%)
occurrences (all)	3	0	1
Dyspepsia			
subjects affected / exposed	2 / 32 (6.25%)	0 / 45 (0.00%)	0 / 18 (0.00%)
occurrences (all)	2	0	0
Glossitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 45 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Nausea			
subjects affected / exposed	7 / 32 (21.88%)	0 / 45 (0.00%)	3 / 18 (16.67%)
occurrences (all)	9	0	3
Oral soft tissue disorder			
subjects affected / exposed	1 / 32 (3.13%)	0 / 45 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Stomatitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 45 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	7 / 32 (21.88%)	0 / 45 (0.00%)	3 / 18 (16.67%)
occurrences (all)	11	0	3
Respiratory, thoracic and mediastinal disorders			
Hiccups			
subjects affected / exposed	6 / 32 (18.75%)	0 / 45 (0.00%)	1 / 18 (5.56%)
occurrences (all)	6	0	1
Sneezing			
subjects affected / exposed	0 / 32 (0.00%)	0 / 45 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 32 (0.00%)	0 / 45 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Psychiatric disorders			
Dysphoria			
subjects affected / exposed	0 / 32 (0.00%)	0 / 45 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1

Infections and infestations Influenza subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 45 (0.00%) 0	1 / 18 (5.56%) 1
Subcutaneous abscess subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 45 (0.00%) 0	1 / 18 (5.56%) 1
Metabolism and nutrition disorders Anorexia subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3	0 / 45 (0.00%) 0	2 / 18 (11.11%) 2
Dehydration subjects affected / exposed occurrences (all)	2 / 32 (6.25%) 2	0 / 45 (0.00%) 0	2 / 18 (11.11%) 2
Decreased appetite subjects affected / exposed occurrences (all)	3 / 32 (9.38%) 3	0 / 45 (0.00%) 0	1 / 18 (5.56%) 1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
27 April 2005	Amendment 01: The protocol was revised to include changes to the Protocol title, Background and Rationale, Patient Inclusion and Exclusion Criteria, and Pharmacokinetic Measurements sections. In addition, there were some minor editorial changes. These changes affected the participation of the participant and the risk/benefit profile. Therefore, modifications to the consent form were required. All new participants and ongoing participants in the study were required to sign the revised consent form.
19 April 2006	Amendment 02: Due to slow enrollment, the protocol was amended. The major changes were: 1) the blinded standard therapy arm was discontinued (referred to as Part One), and all future participants were enrolled into the open-label aprepitant triple therapy arm (referred to as Part Two); 2) the study population was revised to include participants with any confirmed malignancies; rather than only participants with confirmed solid malignancies.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported